Unknown

Dataset Information

0

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.


ABSTRACT: The deployment of a vaccine that limits transmission and disease likely will be required to end the coronavirus disease 2019 (COVID-19) pandemic. We recently described the protective activity of an intranasally administered chimpanzee adenovirus-vectored vaccine encoding a pre-fusion stabilized spike (S) protein (ChAd-SARS-CoV-2-S [chimpanzee adenovirus-severe acute respiratory syndrome-coronavirus-2-S]) in the upper and lower respiratory tracts of mice expressing the human angiotensin-converting enzyme 2 (ACE2) receptor. Here, we show the immunogenicity and protective efficacy of this vaccine in non-human primates. Rhesus macaques were immunized with ChAd-Control or ChAd-SARS-CoV-2-S and challenged 1 month later by combined intranasal and intrabronchial routes with SARS-CoV-2. A single intranasal dose of ChAd-SARS-CoV-2-S induces neutralizing antibodies and T cell responses and limits or prevents infection in the upper and lower respiratory tracts after SARS-CoV-2 challenge. As ChAd-SARS-CoV-2-S confers protection in non-human primates, it is a promising candidate for limiting SARS-CoV-2 infection and transmission in humans.

SUBMITTER: Hassan AO 

PROVIDER: S-EPMC7969912 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8238649 | biostudies-literature
| S-EPMC7442803 | biostudies-literature
| S-EPMC8803102 | biostudies-literature
2020-08-22 | GSE156645 | GEO
| S-EPMC8653296 | biostudies-literature
| S-EPMC6963200 | biostudies-literature
| S-EPMC7865178 | biostudies-literature
| S-EPMC9164439 | biostudies-literature
| S-EPMC8172228 | biostudies-literature
| S-EPMC7581548 | biostudies-literature